Friedrich Miescher Institute for Biomedical Research, Novartis Research Foundation, Basel, Switzerland.
Cell Mol Life Sci. 2012 Jul;69(13):2173-87. doi: 10.1007/s00018-012-0921-9.
Class I Histone deacetylases (HDACs) play a central role in controlling cell cycle regulation, cell differentiation, and tissue development. These enzymes exert their function by deacetylating histones and a growing number of non-histone proteins, thereby regulating gene expression and several other cellular processes. Class I HDACs comprise four members: HDAC1, 2, 3, and 8. Deletion and/or overexpression of these enzymes in mammalian systems has provided important insights about their functions and mechanisms of action which are reviewed here. In particular, unique as well as redundant functions have been identified in several paradigms. Studies with small molecule inhibitors of HDACs have demonstrated the medical relevance of these enzymes and their potential as therapeutic targets in cancer and other pathological conditions. Going forward, better understanding the specific role of individual HDACs in normal physiology as well as in pathological settings will be crucial to exploit this protein family as a useful therapeutic target in a range of diseases. Further dissection of the pathways they impinge on and of their targets, in chromatin or otherwise, will form important avenues of research for the future.
I 类组蛋白去乙酰化酶(HDACs)在调控细胞周期、细胞分化和组织发育中起着核心作用。这些酶通过去乙酰化组蛋白和越来越多的非组蛋白发挥其功能,从而调节基因表达和其他一些细胞过程。I 类 HDAC 包括四个成员:HDAC1、2、3 和 8。在哺乳动物系统中删除和/或过表达这些酶,为它们的功能和作用机制提供了重要的见解,本文对此进行了综述。在几个范例中,已经确定了独特的和冗余的功能。使用 HDAC 的小分子抑制剂的研究表明,这些酶具有医学相关性,并且在癌症和其他病理状况下具有作为治疗靶点的潜力。展望未来,更好地了解单个 HDAC 在正常生理和病理状态下的特定作用,对于将该蛋白家族作为一系列疾病的有用治疗靶点进行开发至关重要。进一步研究它们在染色质或其他方面所影响的途径及其靶标,将成为未来重要的研究途径。